Milciclib in Combination With Gemcitabine in Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goal of this interventional clinical study is to evaluate the safety and efficacy of
Milciclib plus gemcitabine in the treatment of persons with advanced NSCLC. This is an open
label uncontrolled clinical trial
Eligible patients will receive 150 mg/day of milciclib orally using the 7 days on/7 days off
schedule in combination with gemcitabine at the dose of 1000 mg/m² on Days 1, 8, and 15 every
4 weeks. Treatment cycles will be repeated every 4 weeks until progressive disease
(radiologic or symptomatic deterioration), the start of a new systemic anticancer therapy,
unacceptable toxicity, withdrawal per investigator's judgment, or withdrawal of consent,
whichever occurs first.